Annual review of EGFR inhibitors in 2024

IF 6 2区医学 Q1 CHEMISTRY, MEDICINAL

European Journal of Medicinal Chemistry Pub Date : 2025-04-25 DOI:10.1016/j.ejmech.2025.117677

Chao Gao , Wanning Wang , Tong Liu , Xingyu Li , Yongbo Yu , Jianhui Wu

引用次数: 0

Abstract

Epidermal growth factor receptor (EGFR) inhibitors play a crucial role in the treatment of EGFR mutation-driven cancers, such as non-small cell lung cancer (NSCLC). In 2024, significant breakthroughs were made in new drug development, resistance mechanisms, and combination therapy strategies. This review summarizes the key studies published in 2024, with a focus on the design strategies, structure-activity relationships (SAR), mechanisms of action, and both in vitro and in vivo activities of EGFR inhibitors. The aim is to provide new research perspectives and theoretical foundations for developing highly effective and selective inhibitors targeting diverse EGFR mutations.

Abstract Image

查看原文本刊更多论文

2024年EGFR抑制剂年度回顾

表皮生长因子受体（EGFR）抑制剂在治疗EGFR突变驱动的癌症（如非小细胞肺癌（NSCLC））中起着至关重要的作用。2024年，在新药开发、耐药机制、联合治疗策略等方面取得重大突破。本文综述了2024年发表的主要研究成果，重点介绍了EGFR抑制剂的设计策略、构效关系（SAR）、作用机制以及体外和体内活性。旨在为开发针对多种EGFR突变的高效、选择性抑制剂提供新的研究视角和理论基础。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

European Journal of Medicinal Chemistry 化学-医药化学

CiteScore

11.70

自引率

9.00%

发文量

863

审稿时长

29 days

期刊介绍： The European Journal of Medicinal Chemistry is a global journal that publishes studies on all aspects of medicinal chemistry. It provides a medium for publication of original papers and also welcomes critical review papers. A typical paper would report on the organic synthesis, characterization and pharmacological evaluation of compounds. Other topics of interest are drug design, QSAR, molecular modeling, drug-receptor interactions, molecular aspects of drug metabolism, prodrug synthesis and drug targeting. The journal expects manuscripts to present the rational for a study, provide insight into the design of compounds or understanding of mechanism, or clarify the targets.